Company Overview
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Business Model & Competitive Advantage
Regeneron's commercial portfolio is led by Dupixent (dupilumab) — a monoclonal antibody targeting IL-4 and IL-13 for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other allergic/inflammatory conditions. Dupixent has become one of the fastest-growing drugs in pharmaceutical history, with global sales exceeding $14B annually and ongoing label expansion into new indications. Other key products include Eylea (aflibercept) for macular degeneration and diabetic eye disease, Praluent (alirocumab) for high cholesterol, Kevzara (sarilumab) for rheumatoid arthritis, and Libtayo (cemiplimab) for certain skin and lung cancers.
Competitive Landscape 2025–2026
Regeneron trades on NASDAQ (REGN) with a market cap of approximately $55–70B. The company has one of the most productive R&D organizations in biotech — its VelociSuite technology enables rapid antibody and bispecific generation. In 2024, the FDA approved a Dupixent biosimilar competition timeline, creating a long-term revenue headwind that Regeneron is offsetting through new indications and pipeline development including Dupixent for COPD, oncology bispecifics, and obesity programs.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Regeneron Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $13900M in revenue, Regeneron Pharmaceuticals operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Regeneron Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Regeneron Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Regeneron Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Regeneron Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →